Bioscript completed the acquisition of Fortis Pharma and Valid Insight.

Bioscript, a full-service pharmaceutical communications company, completed the acquisition of Fortis Pharma, a London-based specialist in medical affairs services, and Valid Insight, a pharmaceutical global market access consultancy. Financial terms were not disclosed. “These acquisitions are incredibly exciting. At a time of greater trial complexity, rising evidence demands, and tougher economic conditions our clients are looking to us to help navigate demanding access environments and optimise launch success,” Andrew Medley, Bioscript Group CEO.